Practical guidance for CD management involving treatment of botulinum toxin: a consensus statement

Journal of Neurology

Volumn 262, Issue 10, 2015, Pages 2201-2213

  Albanese, Alberto ^a   Abbruzzese, Giovanni ^b   Dressler, Dirk ^c   Duzynski, Wojciech ^d   Khatkova, Svetlana ^e   Marti, Maria Jose ^f   Mir, Pablo ^g,h   Montecucco, Cesare ⁱ   Moro, Elena ^j   Pinter, Michaela ^k   Relja, Maja ^l   Roze, Emmanuel ^m,n   Skogseid, Inger Marie ^o   Timerbaeva, Sofiya ^p   Tzoulis, Charalampos ^q,r  

^a UNIVERSITÀ CATTOLICA DEL SACRO CUORE   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c HANNOVER MEDICAL SCHOOL   (Germany)

^d LUND UNIVERSITY   (Sweden)

^e N N BLOKHIN NATIONAL MEDICAL RESEARCH CENTER OF ONCOLOGY   (Russian Federation)

^f HOSPITAL CLÍNIC   (Spain)

^g HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^h CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

ⁱ UNIVERSITY OF PADOVA   (Italy)

^j GRENOBLE UNIVERSITY HOSPITAL   (France)

^k DANUBE UNIVERSITY KREMS   (Austria)

^l UNIVERSITY OF ZAGREB   (Croatia)

^m PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

ⁿ SORBONNE UNIVERSITÉ   (France)

^o OSLO UNIVERSITY HOSPITAL   (Norway)

^p RESEARCH CENTER OF NEUROLOGY   (Russian Federation)

^q HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^r UNIVERSITY OF BERGEN   (Norway)

more..

Author keywords

Botulinum toxin type A; Botulinum toxins; Consensus development conference; Decision making; Dystonia; Torticollis

Indexed keywords

BOTULINUM TOXIN A; PLACEBO; BOTULINUM TOXIN; NEUROTOXIN;

ABNORMAL POSTURE; CERVICAL DYSTONIA; CONSENSUS; DRUG EFFICACY; DRUG SAFETY; DYSKINESIA; FLU LIKE SYNDROME; HUMAN; INJECTION SITE PAIN; MUSCLE WEAKNESS; NEUROLOGIST; NONHUMAN; PATIENT SATISFACTION; PHYSICIAN; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SOCIAL INTERACTION; TREATMENT OUTCOME; PRACTICE GUIDELINE; TORTICOLLIS;

BOTULINUM TOXINS; CONSENSUS; HUMANS; NEUROTOXINS; PRACTICE GUIDELINES AS TOPIC; TORTICOLLIS;

EID: 84944511294     PISSN: 03405354     EISSN: 14321459     Source Type: Journal    
DOI: 10.1007/s00415-015-7703-x     Document Type: Review

References (94)

1. Charles PD, Adler CH, Stay M et al (2014) Cervical dystonia and pain: characteristics and treatment patterns from CD PROBE (Cervical Dystonia Patient Registry for Observation of OnabotulinumtoxinA Efficacy). J Neurol 261:13019–13098
2. Camfield L, Ben-Shlomo T, Warner TT (2002) Impact of cervical dystonia on quality of life. Mov Disord 17:838–841
3. Jankovic J, Adler CH, Charles PD et al (2011) Rational and design of a prospective study: cervical Dystonia Patient Registry for Observation of OnaBotulinumtoxinA Efficacy (CD PROBE). BMC Neurology 11:140
4. Swope D, Barbano R (2008) Treatment recommendations and practical applications of botulinum toxin treatment of cervical dystonia. Neurol Clin 26(Suppl 1):54–65
5. Albanese A, Asmus F, Bhatia KP et al (2011) EFNS guidelines on diagnosis and treatment of primary dystonias. Eur J Neurol 18:5–18
6. Simpson DM, Blitzer A, Brashear A (2008) Assessment: botulinum neurotoxin for the treatment of movement disorders (an evidence based review): report of the therapeutics and technology assessment subcommittee of the American Academy of Neurology. Neurology 70:1699–1706
7. Murphy MK, Black NA, Lamping DL et al (1998) Consensus development methods, and their use in clinical guideline development. Health Technol Assess 2(no 3):1–88
8. Jankovic J (2006) Treatment of dystonia. Lancet Neurol 5:864–872
9. Tassorelli C, Mancini F, Balloni L et al (2006) Botulinum toxin and neuromotor rehabilitation: an integrated approach to idiopathic cervical dystonia. Mov Disord 21:2240–2243
10. Volkmann J, Mueller J, Deuschl G et al (2014) DBS study group for dystonia. Pallidal neurostimulation in patients with medication-refractory cervical dystonia: a randomised, sham-controlled trial. Lancet Neurol 13(9):875–884. doi:10.1016/S1474-4422(14)70143-7 (Epub 2014 Aug 7)
11. Skogseid IM, Ramm-Pettersen J, Volkmann J, Kerty E, Dietrichs E, Røste GK (2012) Good long-term efficacy of pallidal stimulation in cervical dystonia: a prospective, observer-blinded study. Eur J Neurol 19(4):610–615. doi:10.1111/j.1468-1331.2011.03591.x Epub 2011 Nov 25
12. Albanese A, Barnes MP, Bhatia KP et al (2006) A systematic review on the diagnosis and treatment of primary (idiopathic) dystonia and dystonia plus syndromes: report of an EFNS/MDS-ES task force. Eur J Neurol 13:433–444
13. Colosimo C, Supa A, Fabbrini G et al (2010) Craniocervical dystonia: clinical and pathophysiological features. Eur J Neurol 17(Suppl 1):15–21
14. Zoons E, Dijkgraaf MGW, Dijk JM et al (2012) Botulinum toxin as treatment for focal dystonia: a systematic review of the pharmaco-therapeutic and pharmaco-economic value. J Neurol 259:2519–2526
15. Dressler D, Rothwell JC (2000) Electromyograpjc quantification of the paralysing effect of botulinum toxin in the sternocleidomastoid muscle. Eur Neurol 43(1):13–16
16. Meija NI, Vuong KD, Jankovic J (2005) Long-term botulinum toxin efficacy, safety, and immunogenicity. Mov Disord 20(5):592–597
17. Colosimo C, Tiple D, Berardelli A (2012) Efficacy and safety of long-term botulinum treatment in craniocervical dystonia: a systematic review. Neurotox Res 22:265–273
18. Truong D (2012) Botulinum toxins in the treatment of primary focal dystonias. J Neurolog Sci 316:9–14
19. Jankovic J, Leder S, Warner D, Schwartz K (1991) Cervical dystonia: clinical findings and associated movement disorders. Neurology 41:1088–1091
20. Skogseid IM, Kerty E (2005) The course of cervical dystonia and patient satisfaction with long-term botulinum toxin A treatment. Eur J Neurol 12(3):163–170
21. Skogseid IM, Røislien J (2005) Claussen, Kerty E. Long-term botulinum toxin treatment increases employment rate in patients with cervical dystonia. Mov Disord 20:1604–1609
22. Bove M, Brichetto G, Abbruzzese G, Marchese R, Schieppate M (2004) Neck proprioception and spatial orientation in cervical dystonia. Brain 127(Pt 12):2764–2778
23. Pelosin E, Bove M, Marinelli L, Abbruzzese G, Ghilardi MF (2009) Cervical dystonia affects aimed movements of nonodystonic segments. Mov Disord 24(13):1955–1961
24. Stamelou M, Edwards MJ, Hallett M, Bhatia KP (2012) The non-motor syndrome of primary dystonia: clinical and pathophysiological implications. Brain 135:1668–1681
25. Comella CL, Stebbins GT, Miller S (1996) Specific dystonic factors contributing to work limitation and disability in cervical dystonia. Neurology 46(Suppl 2):A259
26. Stacy M (2008) Epidemiology, clinical presentation, and diagnosis of cervical dystonia. Neurol Clin 26(Suppl 1):23–42
27. Skogseid IM, Malt UF, Røislien J, Kerty E (2007) Determinants and status of quality of life after long-term botulinum toxin therapy for cervical dystonia. Eur J Neurol 14:1129–1137
28. Slawek J, Friedman A, Potulska A et al (2007) Factors affecting health-related quality of life of patients with cervical dystonia and the impact of botulinum toxin type A injections. Funct Neurol 22(2):95–100
29. Hefter H, Benecke R, Erbguth F et al (2013) An open-label cohort study of the improvement in quality of life and pain in de novo cervical dystonia patients after injections with 500U botulinum toxin (Dysport). BMJ Open. doi:10.1136/bmjopen-2112-001853
30. Ben-Shlomo Y, Camfield L, Warner T, ESDE collaborative group (2002) what are the determinants of quality of life in people with cervical dystonia? J Neurol Neurosurg Psychiatry 72:608–614
31. Sethi KD, Rodriguez R, Olayinka B (2012) Satisfaction with botulinum toxin treatment: a cross-sectional survey of patients with cervical dystonia. J Med Econ 15:1–5
32. Albanese A, Bhatia K, Bressman SB et al (2013) Phenomenology and classification of dystonia: a consensus update. Mov Disord 28(7):863–873
33. Albanese A, Lalli S (2009) Is this dystonia? Mov Disord 24(12):1725–1731
34. Lalli S, Albanese A (2010) The diagnostic challenge of primary dystonia: evidence from misdiagnosis. Mov Disord 25(11):1619–1626
35. Moore P, Naumann M (2003) General and clinical aspects of treatment with botulinum toxin. In: Moore P, Naumann M (eds) Handbook of botulinum toxin treatment, 2nd edn. Blackwell Science, Oxford
36. Albanese A, Sorbo FD, Comella C et al (2013) Dystonia rating scale: critique and recommendations. Mov Disord 28:874–883
37. Dressler D, Kupsch A, Seitzinger A, Paus S (2014) The Dystonia Discomfort Scale (DDS): a novel instrument to monitor the temporal profile of botulinum toxin therapy in cervical dystonia. Eur J Neurol. doi:10.1111/ene.12330
38. Reichel G (2011) Cervical dystonia: a new phenomenological classification for botulinum toxin therapy. Basal Ganglia 1:5–12
39. Flowers JM, Hicklin LA, Marion M-H (2011) Anterior and posterior sagittal shift in cervical dystonia: a clinical and electromyographic study, including a new EMG approach of the longus colli muscle. Mov Disord 26(13):2409–2414. doi:10.1002/mds.23905
40. Dressler D (2000) Electromyographic evaluation of cervical dystonia for planning of botulinum toxin therapy. Eur J Neurol 7(6):713–718
41. Lim ECH, Quek AML, Seet RCS (2012) Accurate targeting of botulinum toxin injections: how to and why. Parkinson Rel Dis 17:S34–S39
42. Botox SmPC. http://www.medicines.org.uk/emc/medicine/112
43. Dysport SmPC. http://www.medicines.org.uk/emc/medicine/870
44. Xeomin SmPC. http://www.medicines.org.uk/emc/medicine/20666
45. Neurobloc SmPC. http://www.medicines.org.uk/emc/medicine/20568/SPC
46. Bentovglio AR, Bagella CF, Albanese A (2015) Botulinum toxin in movement disorders. In: Jankovic J, Tolosa E (eds) Parkinson’s disease & Movement Disorders, 6th edn. Wolters Kluver, Philadelphia, pp. 480–495
47. De Pauw J, Van der Velden K, Meirte J et al (2014) The effectiveness of physiotherapy for cervical dystonia: a systematic literature review. J Neurol 261(10):1857–1865. doi:10.1007/s00415-013-7220-8
48. Greene P, Kang U, Fahn S et al (1990) Double-blind, placebo-controlled trial of botulinum toxin injections for the treatment of spasmodic torticollis. Neurology 40:1213–1218
49. Misra VP, Ehler E (2012) Zakine B et al Factors influencing response to Botulinum toxin type A in patients with idiopathic cervical dystonia: results from an international observational study. BMJ Open 2:e000881
50. Dressler D, Tacik P, Adib Saberi F (2015) Botulinum toxin therapy of cervical dystonia: duration of therapeutic effects. J Neural Transm 122(2):297–300
51. ®) in cervical dystonia. J Neural Trans 120(12):1699–1707
52. ® botulinum neurotoxin type A, without accessory proteins) in patients with cervical dystonia. J Neurol Sci 208:103–109
53. Naumann M, Jankovic J (2004) Safety of botulinum toxin type A: a systematic review and meta-analysis. Curr Med Res Opin 20:981–990
54. Borodic GE, Joseph M, Fay L et al (1990) Botulinum toxin for the treatment of spasmodic torticollis: dysphagia and regional toxin spread. Head Neck 12:392–399
55. Borodic GE, Ferrante R, Pearce LB, Smith K (1994) Histologic assessment of dose-related diffusion and muscle fiber response after therapeutic botulinum-A-toxin injection. Mov Disord 9:31–39
56. Hsu TS, Dover JS, Arndt KA (2004) Effect of volume and concentration on the diffusion of botulinum exotoxinA. Arch Dermatol 140:1351–1354
57. Carli L, Montecucco C, Rossatto O (2009) Assay of diffusion of different botulinum toxin type a formulations. Musc Nerve 40:374–380
58. 125I-botulinum-free neurotoxin: time course of tissue distribution. Toxicon 42:461–469
59. Frevert J, Dressler D (2010) Complexing proteins in botulinum toxin type A drugs: a help or a hindrance? Biologics Targets Ther 10:325–332
60. Benecke R, Moore P, Dressler D, Nauman M (2003) Cervical and axial dystonia. In: Moore P, Nauman M (eds) Handbook of botulinum toxin treatment, chap 8, 2nd edn. Blackwell Science, Oxford
61. Aranda MA, Herranz A, del Val J, Belido S, Garcia-Ruiz P (2012) Botulinum toxin A during pregnancy, still a debate. Eur J Eurol 19:e81–e82
62. Brin MF, Comella CL, Jankovic J et al (2008) Long-term treatment with botulinum toxin type A in cervical dystonia has low antigenicity by mouse protection assay. Mov Disord 23:1353–1360
63. Dressler D (1997) Botulinum toxin therapy failure: causes, evaluation procedures and management strategies. Eur J Neurol 4(suppl 2):S67–S70
64. Ferreria JJ, Bhidayasiri R, Colosimo C et al (2012) Survey of practices employed by neurologists for the definition and management of secondary non-response to botulinum toxin in cervical dystonia. Funct Neurol 27(4):225–230
65. ®) in focal dystonia. Drugs 67:669–683
66. Cordivari C, Misra VP, Vincent A et al (2006) Secondary nonresponsiveness to botulinum toxin A in cervical dystonia: the role of electromyogram-guided injections, botulinum toxin A antibody assay, and the extensor digitorum brevis test. Mov Disord 21:1737–1741
67. Dressler D, Gessler F, Tacik P, Bigalke H (2014) An enzyme-linked immunosorbent assay for detection of botulinum toxin antibodies. Mov Disord 29(10):1322–1324. doi:10.1002/mds.25956
68. Walsh RA, Sidiropoulos C, Lozano AM et al (2013) Bilateral pallidal stimulation in cervical dystonia: blinded evidence of benefit beyond 5 years. Brain 136:761–769
69. Wohlfarth K, Schwandt I, Wegner F et al (2008) Biological activity of two botulinum toxin type A complexes (Dysport and Botox) in volunteers: a double-blind, randomized, dose-ranging study. J Neurol 255(12):1932–1939
70. Marchetti A, Magar R et al (2005) Retrospective Evaluation of the Dose of Dysport and BOTOX in the Management of Cervical Dystonia and Blepharospasm: The REAL DOSE Study. Mov Disord 20(8):937–944
71. Wohlfarth K, Sycha T, Ranoux D et al (2009) Dose equivalence in two preparations of botulinum toxin type A: time for a reassessment? Curr Med Res Opin 25:1573–1584
72. ® formulation of botulinum toxin: clinical experience in 257 cases. Botulinum J 2(3/4):276
73. ®). J Neural Trans 121:29–31
74. Odergren T, Hjaltason H (1998) Kaakkola S et al A double-blind randomised, parallel-group study to investigate the dose equivalence of Dysport and Botox in the treatment of cervical dystonia. J Neurol Neurosurg Psychiatr 64:6–12
75. Bihari K (2005) Safety, effectiveness and duration of effect of BOTOX compared with Dysport for blepharospasm, cervical dystonia and hemifacial spasm. Curr Med Res Opin 21(3):433–438
76. Ranoux D et al (2002) Respective potencies of Botox and Dysport: a double blind, randomized, crossover study in cervical dystonia. J Neurol Neurosurg Psychiatry 72:459–462
77. Chapman MA, Barron R, Tanis DC et al (2007) Comparison of botulinum neurotoxin preparations for the treatment of cervical dystonia. Clin Ther 29:1325–1337
78. Hunt T, Clarke K (2009) Potency evaluation of a formulated drug product containing 150-kd botulinum neurotoxin type A. Clin Neuropharm 32:28–31
79. ®) in healthy volunteers. J Neural Transm 112:905–913
80. Benecke R, Jost WH, Kanovsky P et al (2005) A new botulinum toxin type A free of complexing proteins for treatment of cervical dystonia. Neurology 64:1949–1951
81. Roggenkämper P, Jost WH, Bihari K et al (2006) Efficacy and safety of a new botulinum toxin type A free of complexing proteins in the treatment of blepharospasm. J Neural Trans 113:303–312
82. Dressler D (2009) Routine use of Xeomin in patients previously treated with Botox: long-term results. Eur J Neurol 16(Suppl 2):2–5
83. Benecke R (2009) Current status of the use of botulinum neurotoxin type A. Eur J Neurol 16(Suppl 2):1. doi:10.1111/j.1468-1331.2009.02876.x
84. Benecke R, Hauschke D (2013) IncobotulinumtoxinA demonstrated equivalent efficacy to onabotulinumtoxinA in the treatment of cervical dystonia. Botulinum J 2(3/4):217
85. Lowe NJ, Yamauchi PS, Lask GP et al (2002) Botulinum toxins types A and B for brow furrows: preliminary experience with type B toxin dosing. J Cosmet Laser Ther 4:15–18
86. Blitzer A (2005) Botulinum toxin A and B: a comparative dosing study for spasmodic dysphonia. Otolaryngol Head and Neck Surg 133:836–838
87. Kranz G, Paul A, Voller B et al (2011) Long-term efficacy and respective potencies of botulinum toxin A and B: a randomized, double-blind study. Br J Dermatol 164:176–181
88. Poewe W, Deuschl G, Nebe A et al (1998) What is the optimal dose of botulinum toxin A in the treatment of cervical dystonia? Results of a double-blind placebo controlled dose ranging study of Dysport. German Dystonia Study Group. J Neurol Neurosurg Psychiatr 64:13–17
89. Truong D, Duane DD, Jankovic J et al (2005) Efficacy and safety of botulinum type A toxin (Dysport) in cervical dystonia: results of the first US randomised, double-blind, placebo-controlled study. Mov Disord 20:783–791
90. Truong DD, Brodsky M (2010) Lew M et al Long-term efficacy and safety of botulinum toxin type A (Dysport) in cervical dystonia. Parkinsonism Relat Disord 16:316–323
91. Brans JW, Lindeboom R (1996) Snoek JW et al Botulinum toxin versus trihexyphenidyl in cervical dystonia: a prospective, randomized, double-blind controlled trial. Neurology 46:1066–1072
92. Pappert EJ, Germanson T, Myobloc/Neurobloc European Cervical Dystonia Study Group (2008) Botulinum toxin type B vs. type A in toxin naive patients with cervical dystonia: randomized, double-blind, noninferiority trial. Mov Disord 23:510–517
93. Comella CL, Jankovic J, Shannon KM, Dystonia Study Group et al (2005) Comparison of botulinum toxin serotypes A and B for the treatment of cervical dystonia. Neurology 65:1423–1429
94. Novak Campbell L, Boyce M, Fung VSC (2010) Botulinum toxin assessment, intervention and aftercare for cervical dystonia and other causes of hypertonia of the neck: international consensus statement. Eur J Neurol 17(Suppl 2):94–108